Hormone replacement therapy and breast cancer: Heterogeneous risks by race, weight, and breast density

Journal of the National Cancer Institute

Volumn 105, Issue 18, 2013, Pages 1365-1372

  Hou, Ningqi ^a   Hong, Susan ^a   Wang, Wenli ^b   Olopade, Olufunmilayo I ^a   Dignam, James J ^a   Huo, Dezheng ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ASIAN; BODY MASS; BODY WEIGHT; BREAST; BREAST CANCER; CANCER RISK; DENSITY; FEMALE; GROUPS BY AGE; HIGH RISK POPULATION; HISPANIC; HORMONE SUBSTITUTION; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NEGRO; OBESITY; PACIFIC ISLANDER; POSTMENOPAUSE; PRIORITY JOURNAL; RACE DIFFERENCE; REGISTER; UNITED STATES;

AFRICAN AMERICANS; AGED; ASIAN AMERICANS; BODY MASS INDEX; BODY WEIGHT; BREAST; BREAST NEOPLASMS; CONTINENTAL POPULATION GROUPS; EARLY DETECTION OF CANCER; ESTROGEN REPLACEMENT THERAPY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MAMMOGRAPHY; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84886888847     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt207     Document Type: Article

References (38)

1. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med. 1994;330(15): 1062-1071.
2. Ross RK, Paganini-Hill A, Wan PC, et al. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92(4): 328-332.
3. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350(9084): 1047-1059.
4. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382): 419-427.
5. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289(24): 3243-3253.
6. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291(1): 47-53.
7. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007;9(3):R28.
8. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat. 2008;107(3): 427-430.
9. Li CI, Daling JR. Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev. 2007;16(12): 2773-80.
10. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breastcancer incidence in 2003 in the United States. N Engl J Med. 2007;356(16): 1670-1674.
11. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009;360(6): 573-587.
12. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3): 321-333.
13. Shoupe D. Individualizing hormone therapy to minimize risk: accurate assessment of risks and benefits. Womens Health (Lond Engl). 2011;7(4): 475-485.
14. Beral V, Reeves G, Bull D, et al. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. 2011;103(4): 296-305.
15. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15): 1684-1692.
16. Fournier A, Mesrine S, Boutron-Ruault MC, et al. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol. 2009;27(31): 5138-5143.
17. Kerlikowske K, Cook AJ, Buist DS, et al. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. J Clin Oncol. 2010;28(24): 3830-3837.
18. Rosenberg L, Palmer JR, Wise LA, et al. A prospective study of female hormone use and breast cancer among black women. Arch Intern Med. 2006;166(7): 760-765.
19. Hall IJ, Moorman PG, Millikan RC, et al. Comparative analysis of breast cancer risk factors among African-American women and white women. AmJ Epidemiol. 2005;161(1): 40-51.
20. Martin KA, Manson JE. Approach to the patient with menopausal symptoms. J Clin Endocrinol Metab. 2008;93(12): 4567-4575.
21. Ballard-Barbash R, Taplin SH, Yankaskas BC, et al. Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. Am J Roentgenol. 1997;169(4): 1001-1008.
22. Carney PA, Geller BM, Moffett H, et al. Current medicolegal and confidentiality issues in large, multicenter research programs. Am J Epidemio.I 2000;152(4): 371-378.
23. Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med. 2003;138(3): 168-175.
24. Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst. 2006;98(17): 1204-1214.
25. Van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18(6): 681-694.
26. Royston P. Multiple imputation of missing values. Stata J. 2004;4(3): 227-241.
27. Royston P. Multiple imputation of missing values: further update of ice, with an emphasis on categorical variables. Stata J. 2009;9(3): 466-477.
28. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4): 377-399.
29. Hou N, Huo D. A trend analysis of breast cancer incidence rates in the United States from 2000 to 2009 shows a recent increase. Breast Cancer Res Treat. 2013;138(2): 633-641.
30. Breen N, K AC, Meissner HI, et al. Reported drop in mammography: is this cause for concern? Cancer. 2007;109(12): 2405-2409.
31. Ryerson AB, Miller JW, Eheman CR, et al. Recent trends in U.S. mammography use from 2000-2006: a population-based analysis. Prev Med. 2008;47(5): 477-482.
32. Reeves GK, Beral V, Green J, et al. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol. 2006;7(11): 910-918.
33. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen- progestin replacement therapy and breast cancer risk. JAMA. 2000;283(4): 485-491.
34. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14): 1701-1712.
35. Brisson J, Morrison AS, Kopans DB, et al. Height and weight, mammographic features of breast tissue, and breast cancer risk. Am J Epidemiol. 1984;119(3): 371-381.
36. Greendale GA, Reboussin BA, Slone S, et al. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst. 2003;95(1): 30-37.
37. McTiernan A, Martin CF, Peck JD, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst. 2005;97(18): 1366-1376.
38. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305(13): 1305-1314.